{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:05:54Z","timestamp":1783926354298,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220232"],"award-info":[{"award-number":["RP220232"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP160805"],"award-info":[{"award-number":["RP160805"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["H-Q-0042"],"award-info":[{"award-number":["H-Q-0042"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118989","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:48:43Z","timestamp":1779205723000},"page":"118989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis, structure-activity relationships, antitumor activities and mechanistic studies of ENL-degrading compounds"],"prefix":"10.1016","volume":"316","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshavardhan Reddy","family":"Kasireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Bhushan","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala Krishna","family":"Moku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118989_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nature21687","article-title":"ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia","volume":"543","author":"Wan","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118989_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature21688","article-title":"Transcription control by the ENL YEATS domain in acute leukaemia","volume":"543","author":"Erb","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118989_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01057-7","article-title":"Structure, function and inhibition of critical protein\u2013protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118989_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118989_bib5","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/sj.leu.2404903","article-title":"Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan infant leukemia study group","volume":"21","author":"Tomizawa","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118989_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","article-title":"Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the children's oncology group","volume":"108","author":"Hilden","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118989_bib7","series-title":"Molecular Rearrangements on Chromosome 11q23 Predominate in Infant Acute Lymphoblastic Leukemia and Are Associated with Specific Biologic Variables and Poor Outcome","author":"Chen","year":"1993"},{"key":"10.1016\/j.ejmech.2026.118989_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10013","article-title":"MLLT1 YEATS domain mutations in clinically distinctive favourable histology wilms tumours","volume":"6","author":"Perlman","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118989_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2472555218809904","article-title":"Discovery of a selective inhibitor for the YEATS domains of ENL\/AF9","volume":"24","author":"Christott","year":"2019","journal-title":"SLAS DISCOVERY: Advancing the Science of Drug Discovery"},{"key":"10.1016\/j.ejmech.2026.118989_bib10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cell.2014.09.049","article-title":"AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation","volume":"159","author":"Li","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118989_bib11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0960-9822(02)00901-6","article-title":"Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain","volume":"12","author":"Feng","year":"2002","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2026.118989_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118989_bib13","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.7150\/thno.56737","article-title":"Small-molecule inhibitor of AF9\/ENL-DOT1L\/AF4\/AFF4 interactions suppresses malignant gene expression and tumor growth","volume":"11","author":"Wu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.118989_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.str.2012.11.011","article-title":"Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding","volume":"21","author":"Leach","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118989_bib15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.celrep.2015.04.004","article-title":"Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di-and tri-methylation on target genes and transformation potential","volume":"11","author":"Kuntimaddi","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118989_bib16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccr.2011.09.008","article-title":"CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis","volume":"20","author":"Tan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118989_bib17","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.celrep.2013.03.038","article-title":"MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells","volume":"3","author":"Maethner","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118989_bib18","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1038\/sj.onc.1206361","article-title":"The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor","volume":"22","author":"Srinivasan","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118989_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ccr.2009.12.040","article-title":"A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-Dependent transcription","volume":"17","author":"Yokoyama","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118989_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","article-title":"AFF4, a component of the ELL\/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia","volume":"37","author":"Lin","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118989_bib21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1101\/gad.1898410","article-title":"Linking H3K79 trimethylation to wnt signaling through a novel Dot1-containing complex (DotCom)","volume":"24","author":"Mohan","year":"2010","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmech.2026.118989_bib22","doi-asserted-by":"crossref","first-page":"16302","DOI":"10.1002\/anie.201810617","article-title":"Discovery of an MLLT1\/3 YEATS domain chemical probe","volume":"57","author":"Moustakim","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.118989_bib23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/acscentsci.0c01550","article-title":"Chemical inhibition of ENL\/AF9 YEATS domains in acute leukemia","volume":"7","author":"Garnar-Wortzel","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2026.118989_bib24","doi-asserted-by":"crossref","first-page":"10997","DOI":"10.1021\/acs.jmedchem.1c00367","article-title":"Discovery of selective small-molecule inhibitors for the ENL YEATS domain","volume":"64","author":"Ma","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118989_bib25","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/2159-8290.CD-21-1307","article-title":"Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia","volume":"12","author":"Liu","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118989_bib26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118989_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118989_bib28","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.118989_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01258-8","article-title":"A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118989_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado1432","article-title":"A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression","volume":"10","author":"Xue","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.118989_bib31","first-page":"1","article-title":"High-throughput ligand diversification to discover chemical inducers of proximity","author":"Shaum","year":"2026","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118989_bib32","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1021\/acs.jmedchem.8b01457","article-title":"Structure-based approach toward identification of inhibitory fragments for eleven-nineteen-leukemia protein (ENL)","volume":"61","author":"Heidenreich","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118989_bib33","doi-asserted-by":"crossref","first-page":"10917","DOI":"10.1021\/acs.jmedchem.3c00736","article-title":"Small-molecule hydrophobic tagging: a promising strategy of druglike technology for targeted protein degradation: miniperspective","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118989_bib34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jb\/mvp139","article-title":"Quality control against misfolded proteins in the cytosol: a network for cell survival","volume":"146","author":"Kubota","year":"2009","journal-title":"J. Biochem."},{"key":"10.1016\/j.ejmech.2026.118989_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026057","article-title":"Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation","volume":"6","author":"Ji","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118989_bib36","series-title":"Cold Spring Harbor Symposia on Quantitative Biology","first-page":"61","article-title":"The essential transcriptional function of BRD4 in acute myeloid leukemia","author":"Roe","year":"2016"},{"key":"10.1016\/j.ejmech.2026.118989_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:16:30Z","timestamp":1783923390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S0223523426004344"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118989","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, structure-activity relationships, antitumor activities and mechanistic studies of ENL-degrading compounds","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118989"}}